Neurology 2019 04 27;92(17):e1982-e1991. Epub 2019 Mar 27.
From the Parkinson-Klinik Ortenau (W.H.J.), Wolfach, Germany; Department of Neurology (A.F.), Faculty of Health Science, Medical University of Warsaw, Poland; Department of Otorhinolaryngology (O.M.), University Hospital Brussels, Vrije Universiteit Brussel, Belgium; Neurological Outpatient Clinic for Parkinson's Disease and Deep Brain Stimulation (C.O.), Gera, Germany; Department of Neurological-Psychiatric Nursing (J.S.), Medical University of Gdansk; Neurology Department (J.S.), St. Adalbert Hospital, Gdansk; Department of Extrapyramidal Diseases (A. Bogucki), Medical University of Łódź; Department of Neurology and Stroke Unit (S.O.), Medical University of Silesia, Katowice; Department of Neurology (M.B.), Collegium Medicum, Jagiellonian University, Krakow, Poland; Department of Neurology (F.P.), Georgetown University Hospital, Washington, DC; Merz Pharmaceuticals GmbH (B.F.-B., J.C.), Frankfurt am Main, Germany; Complete Medical Communications (C.J.C.), Glasgow, UK; Department of Otolaryngology/Head and Neck Surgery (A. Blitzer), Columbia University College of Physicians and Surgeons, New York; Department of Neurology (A. Blitzer), Icahn School of Medicine at Mt. Sinai, New York; and NY Center for Voice and Swallowing Disorders (A. Blitzer), New York, NY.
Objective: This pivotal phase III study, SIAXI, investigated the efficacy and safety of incobotulinumtoxinA for the treatment of chronic sialorrhea due to Parkinson disease (PD), atypical parkinsonism, stroke, or traumatic brain injury (TBI).
Methods: Adult patients with PD (70.7%), atypical parkinsonism (8. Read More